LH

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 1995, for Laboratory Corporation of America Holdings (formerly NationalHealth Laboratories Holdings Inc.). The reporting period is significantly impacted by the April 28, 1995, merger with Roche Biomedical Laboratories, Inc. (RBL), which accounted for approximately 49.8% of the increase in net sales for the nine-month period. The company operates as a provider of clinical laboratory services.

Key Financial Metrics

Note: Total Debt calculated as Current portion of long-term debt ($68.8M) + Revolving credit facility ($218.0M) + Long-term debt ($731.2M) + Capital lease obligation ($9.8M) = $1,027.8M. However, the text highlights a $800M Term Loan and $450M Revolving facility. The balance sheet shows Total Current Liabilities of $311.8M and Long-term debt of $731.2M plus Revolving of $218.0M. The specific debt figure of $800.0M cited in the text refers to the new Term Loan Facility.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 61.3% year-over-year for the nine-month period, driven primarily by the RBL merger ($317.8M increase) and the prior acquisition of Allied Clinical Laboratories ($56.6M increase).
• Profitability Decline: Despite revenue growth, Net Earnings turned to a loss of $12.7M compared to $22.4M in the prior year. This was caused by significant non-recurring charges.
• Restructuring Charges: The company recorded a $65.0M restructuring charge in the second quarter to close duplicate facilities and reduce workforce by approximately 2,200 employees following the merger.
• Settlement Provision: A $10.0M pre-tax charge was taken for estimated costs of settling billing disputes and other claims.
• Extraordinary Loss: An $8.3M net-of-tax loss was recorded due to the early extinguishment of debt associated with refinancing for the merger.
• Debt Increase: Long-term debt increased substantially to finance the merger cash consideration ($474.8M paid to shareholders) and refinance existing obligations. The company entered a new credit agreement with an $800M Term Loan and $450M Revolving Facility.

Guidance, Outlook, and Risks

• Cost Synergies: Management expects to realize annualized net savings of $100.0M to $110.0M within three years post-merger through consolidation of operations, elimination of redundant staff, and facility closures.
• Regulatory Risks: A reduction in Medicare fee schedules to 76% of median fee amounts, effective January 1, 1996, is expected to negatively impact net sales and margins. Further legislative changes are pending in Congress.
• Market Conditions: Management anticipates continued price erosion and lower utilization of laboratory testing in the industry, which will negatively impact results.
• Liquidity: The company expects to meet working capital and capital expenditure needs (estimated at $75M for 1995) through operating cash flows and borrowings under the Revolving Credit Facility.
• Interest Rate Management: The company entered into interest rate swap agreements to fix the rate on $600M of floating rate debt at a weighted average of 6.01% through September 1998.

Investor Verification Checklist

• Verify the realization of the projected $100M-$110M in annualized cost savings from the RBL merger integration.
• Monitor the impact of the January 1, 1996, Medicare fee schedule reduction on gross margins and net sales.
• Assess the company's ability to service its increased debt load ($800M Term Loan + Revolver) given the current operating cash flow of $4.4M for the nine-month period.
• Track the progress of the restructuring plan, specifically the closure of duplicate facilities and the reduction of 2,200 employees.
• Review the status of pending billing disputes and the adequacy of the $10.0M settlement provision.